(Favezelimab + pembrolizumab) is under clinical development by Merck and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Favezelimab + pembrolizumab)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Favezelimab + pembrolizumab) overview
MK-4280A is under development for the treatment of metastatic renal cell carcinoma (mRCC), melanoma, small-cell lung cancer, esophageal cancer, relapsed or refractory classical Hodgkin lymphoma, non muscle invasive bladder cancer, metastatic urothelial carcinoma, cutaneous squamous cell carcinoma (cSCC) and endometrial cancer (EC) and metastatic colorectal cancer. It is administered intravenously and is a fixed dose combination of favezelimab and pembrolizumab. Favezelimab is an anti-LAG3 monoclonal antibody and pembrolizumab is an anti-PD-1 monoclonal antibody.
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
For a complete picture of (Favezelimab + pembrolizumab)’s drug-specific PTSR and LoA scores, buy the report here.